Insomnia With Poor Sleep Quality: Pathophysiology, Risk Factors, Assessment, and Evidence-Based Treatment Strategies

Insomnia with poor sleep quality is a common sleep-wake disorder characterized by dissatisfaction with sleep, difficulty initiating sleep, difficulty maintaining sleep, or early-morning awakenings, occurring despite adequate opportunity for sleep. Clinically, it is not merely “feeling tired”; it reflects measurable impairment in sleep continuity and/or sleep architecture, often accompanied by cognitive, emotional, and physical consequences. Sleep quality may be poor even when total sleep time seems adequate, because fragmentation, abnormal timing, or reduced restorative sleep (e.g., diminished slow-wave sleep or altered REM density) can drive persistent daytime symptoms.

Mechanistically, insomnia is frequently maintained by a bidirectional loop between hyperarousal and conditioned sleep-prevention. Hyperarousal involves heightened sympathetic activity, increased cognitive rumination, and dysregulated stress physiology, including altered hypothalamic-pituitary-adrenal (HPA) axis signaling and changes in cortisol rhythm. Patients may experience increased cortical activation at night, with reduced parasympathetic tone, making it harder to “downshift” into sleep. Conditioning occurs when the bed and bedroom become associated with wakefulness, worry, and effortful attempts to sleep. This can lead to increased time in bed while awake, which further reinforces the perception of poor sleep quality.

At the neurobiological level, insomnia is associated with dysregulation in arousal systems (e.g., orexin/hypocretin pathways, serotonergic and noradrenergic signaling) and altered thalamocortical dynamics. The sleep spindle and slow-wave generation processes can be disrupted, contributing to nonrestorative sleep. Neuroinflammation and metabolic factors have also been implicated in some populations, particularly those with comorbid mood disorders, pain, obesity, or cardiometabolic disease.

Risk factors include psychological stress, anxiety and depression, irregular schedules (circadian misalignment), screen exposure and late-night light, caffeine or nicotine use, alcohol-related sleep fragmentation, and shift work. Medical and psychiatric comorbidities are common: restless legs syndrome, obstructive sleep apnea, chronic pain syndromes, gastroesophageal reflux, asthma, and menopause-related symptoms can all degrade sleep continuity. Certain medications—such as corticosteroids, some antidepressants, beta-agonists, decongestants, stimulants, and some thyroid therapies—may worsen insomnia.

Assessment begins with a detailed sleep history: sleep latency, awakenings, total sleep time, circadian timing, sleep environment, and daytime impairment. Standardized tools include the Insomnia Severity Index (ISI) and sleep diaries, which capture day-to-day variability and help identify precipitating and perpetuating factors. Actigraphy may be used when patterns are unclear. If symptoms suggest another disorder, such as snoring, witnessed apneas, or excessive daytime sleepiness, evaluation for sleep-disordered breathing is warranted; for limb sensations and urge to move at night, restless legs syndrome should be considered.

Treatment is most effective when targeted to maintaining mechanisms. First-line therapy for chronic insomnia is Cognitive Behavioral Therapy for Insomnia (CBT-I). CBT-I includes stimulus control (strengthening the bed/bedroom association with sleep), sleep restriction (limiting time in bed to consolidate sleep and reduce fragmentation), cognitive restructuring (addressing dysfunctional beliefs about sleep and catastrophic worry), and relaxation strategies. Chronotherapy and circadian interventions may be added when circadian misalignment is prominent, such as using consistent wake times and morning light exposure.

Pharmacologic therapy can be considered for short-term relief in selected patients, particularly when immediate symptom burden is high or while CBT-I is being initiated. Options include non-benzodiazepine hypnotics (e.g., Z-drugs), melatonin or melatonin receptor agonists in appropriate circadian contexts, and orexin receptor antagonists. Sedating antihistamines are generally less favored due to anticholinergic effects and next-day impairment. Medication choice should account for comorbidities, fall risk, substance use, pregnancy status, and potential drug interactions. Benzodiazepines may be used cautiously and typically not as long-term solutions due to tolerance, dependence, and adverse cognitive effects.

Sleep hygiene is supportive but rarely sufficient alone. Nonetheless, evidence-informed habits include maintaining consistent sleep timing, limiting caffeine after midday, avoiding late nicotine, reducing alcohol close to bedtime, minimizing evening screen exposure or using blue-light reduction, and creating a dark, cool, quiet environment. Patients should be counseled that insomnia is often reversible, but requires addressing both physiological hyperarousal and cognitive-behavioral perpetuation.

When insomnia is severe or persistent, clinicians should evaluate for emergent safety concerns such as suicidality in mood disorders, significant substance misuse, or uncontrolled medical illness. Persistent poor sleep quality can worsen concentration, mood regulation, pain sensitivity, and cardiometabolic risk. Therefore, early identification and structured therapy—particularly CBT-I—are recommended to restore sleep continuity, improve daytime function, and reduce long-term morbidity.

Source: @alchymycal